期刊文献+

抗人DR5单克隆抗体诱导Jurkat和U937细胞凋亡的线粒体信号通路 被引量:2

Anti-human DR5 monoclonal antibody induced apoptosis in Jurkat/U937 cell by mitochondrial signal pathway
下载PDF
导出
摘要 目的:探讨抗人死亡受体5(Death receptor 5,DR5)单克隆抗体mDRA-6诱导Jurkat和U937细胞凋亡的线粒体信号通路。方法:MTT法检测mDRA-6对Jurkat和U937细胞生长增殖的影响,以及caspase-9、3抑制剂对mDRA-6抑制Jur-kat和U937细胞生长增殖的影响;琼脂糖凝胶电泳检测Jurkat和U937细胞DNA片段化降解;Western blot检测mDRA-6对Jurkat和U937细胞bax、bcl-2、bcl-xl、Cyt c及caspase-9、3的激活改变。结果:mDRA-6呈时间、浓度依赖性地抑制Jurkat和U937细胞的生长增殖,10 mg/L的mDRA-6作用6、8和10小时,Jurkat细胞增殖抑制率分别达59.38%、72.56%和76.28%,U937细胞增殖抑制率分别达38.67%、47.54%和50.59%。琼脂糖凝胶电泳显示,10 mg/L的mDRA-6作用6小时,Jurkat和U937细胞均呈现凋亡细胞特有的DNA梯形条带;Western blot检测结果发现,随着mDRA-6作用时间延长,Jurkat和U937细胞内促凋亡分子bax增多,抗凋亡分子bcl-2及bcl-xl减少,Cyt c释放明显增多,同时caspase-9、caspase-3也显示明显的激活表现。预先使用caspase-9抑制剂孵育细胞1小时,mDRA-6所致Jurkat和U937细胞生长抑制率分别降低了24.36%(t=5.44,P﹤0.01)和20.82%(t=4.29,P﹤0.01),mDRA-6所致Jurkat和U937细胞凋亡率分别降低了32.89%和23.97%。结论:线粒体信号通路激活是抗人死亡受体5(Death receptor 5,DR5)单克隆抗体mDRA-6诱导Jurkat和U937细胞凋亡的途径之一。 Objective:To explore the mitochondrial pathway in the apoptosis of Jurkat and U937 cells induced by anti-human DR5 monoclonal antibody-mDRA-6.Methods:The inhibition and apoptosis of Jurkat and U937 cells after treating with mDRA-6 or/and caspases inhibitors were analyzed using MTT and FITC Annexin V/PI staining.The DNA ladder of Jurkat and U937 cells treated with mDRA-6(10 mg/L) for 6 h was analyzed by 1% agrose gel electrophoresis.The expression of bax,bcl-2,bcl-xl,Cyt c,caspase-9,caspase-3 of Jurkat and U937 cells after treating with mDRA-6 were detected by Western blot,respectively.Results:The proliferation of Jurkat and U937 cell after treating with mDRA-6 was inhibited in dose-dependent and time-dependent manner;DNA fragmentation detection indicated Jurkat and U937 cell apoptosis induced by mDRA-6.When the cells were treated with mDRA-6,analysis by immunoblotting indicated that bax and Cyt c was increased,while bcl-2 and bcl-xl was decreased in time dependent manner,caspases-9 and caspases-3 were activated in Jurkat and U937 cells.Jurkat and U937 cells were incubated with the inhibitors of caspase-9 for one hour,respectively,and then the cells were treated with mDRA-6,Jurkat and U937 cells inhibition induced by mDRA-6 were reduced by 24.36%(t=5.44,P﹤0.01) and 20.82%(t=4.29,P﹤0.01),Jurkat and U937 cells apoptosis induced by mDRA-6 were reduced by 32.89% and 23.97%,respectively.Conclusion:Anti-human DR5 monoclonal antibody-mDRA-6 induce the apoptosis of Jurkat and U937 cells through involves mitochondrial signal pathway.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2012年第12期1068-1072,共5页 Chinese Journal of Immunology
基金 国家"重大新药创制"科技重大专项(No.2011ZX09506-004)
关键词 死亡受体5 单克隆抗体 凋亡 线粒体 Death receptor 5 Monoclonal antibody Apoptosis Mitochondria
  • 相关文献

参考文献14

  • 1Sarah S,Alexandre M,Olivier M. Regulating TRAIL receptor-induced cell death at the membrane:a deadly discussion[J].Recent Pat Anticancer Drug Discov,2011,(03):311-323.
  • 2Duiker E W,Mom C H,Jong S. The clinical trail of TRAIL[J].European Journal of Cancer,2006.2233-2240.
  • 3Mérino D,Lalaoui N,Morizot A. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2[J].Molecular and Cellular Biology,2006.7046-7055.
  • 4Gaelle P,Valerie T,Stephane T. TRAIL receptor signaling and therapeutic option in bone tumors:the trap of the bone microenvironment[J].Am J Cancer Res,2012,(01):45-64.
  • 5Pennarun B,Meijer A,de Vries E G. Playing the DISC:turning on TRAIL death receptor-mediated apoptosis in cancer[J].Biochimica Et Biophysica Acta,2010,(02):123-140.
  • 6Walczak H,Haas T L. Biochemical analysis of the native TRAIL death-inducing signaling complex[J].Methods in Molecular Biology,2008.221-239.
  • 7Koschny R,Walczak H,Ganten T M. The promise of TRAIL-potential and risks of a novel anticancer therapy[J].Journal of Molecular Medicine,2007,(09):923-935.
  • 8Nadzeva G K,Denis L,Isabelle M. Targeted ovarian cancer treatment:the TRAILs of resistance[J].Am J Cancer Res,2012,(01):75-92.
  • 9Greco F A,Bonomi P,Craw ford J. Phase 2 study of mapatumumab,a fully human agonistic monoclonal ant ibody which target sand activates the TRAIL receptor1 inpatients with advanced nonsmall cell[J].Lung Cancer,2008,(01):82-90.doi:10.1016/j.lungcan.2007.12.011.
  • 10Tolcher A W,Mita M,Mer opol N J. PhaseⅠpharmacokinetic and biologic correlative study of mapatumumab,a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor[J].Journal of Clinical Oncology,2007,(11):1390-1395.

二级参考文献8

共引文献4

同被引文献29

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部